well I told you someone would buy $CLDA, certainly disappointed in the low ball offer though. I never had sky high expectations, but the deal doesn't respect the value of Stediavase or any other their pipeline. I had imagined a deal would be done closer to the high $30s - low $40s. I imagine Kirk et al. will have a fun time with all the lawsuits over the next month or so.
It turns out the FDA thought so highly of one of GTCB's employees, they gave him a job reviewing applications. Not sure whether this is the one in question or a TEVA one.
News 
Market Data 
Discover 
